Gracell Biotechnologies Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Gracell Biotechnologies Inc. | GRCL - NASDAQ |
$16.00-$18.00 | $19.00 | $26.00 | 11 million | 1/8/2021 |
| Citigroup, Jefferies, Piper Sandler, Wells Fargo | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-12-18 Terms Added 2021-01-01 Terms Changed 2021-01-07 Terms Changed 2021-01-07 Terms Changed 2021-01-07 | ||||||
Gracell Biotechnologies Inc. Quote & Chart - Click for current quote - GRCL
IPO Boutique aggregates information on public companies and private companies, such as "GRCL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Gracell Biotechnologies Inc. (adapted from Gracell Biotechnologies Inc. prospectus):
They are a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "GRCL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.